Athenex, Inc. (ATNX) News

Athenex, Inc. (ATNX): $0.96

0.33 (+51.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ATNX News Items

ATNX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ATNX News Highlights

  • For ATNX, its 30 day story count is now at 8.
  • Over the past 13 days, the trend for ATNX's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • The most mentioned tickers in articles about ATNX are IBRX.

Latest ATNX News From Around the Web

Below are the latest news stories about Athenex Inc that investors may wish to consider to help them evaluate ATNX as an investment opportunity.

Athenex names new CFO

Athenex (NASDAQ:ATNX) has appointed Joe Annoni as its new chief financial officer and officer of the company, effective immediately. Prior to joining Athenex, Annoni served as Managing Director with GFW Partners, a boutique advisory firm. Prior to GFW, Joe was a founding member of NHA Capital where he led private equity and...

Seeking Alpha | February 22, 2022

Athenex Announces Appointment of Chief Financial Officer

BUFFALO, N.Y., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that Mr. Joe Annoni will join Athenex as its new Chief Financial Officer and Officer of the Company, effective immediately. Mr. Annoni is an accomplished financial professional and has enjoyed a multi-faceted career in private equity,

Yahoo | February 22, 2022

Athenex Announces Completion of Sale of Dunkirk Manufacturing Facility

BUFFALO, N.Y., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today the close of the sale of its leasehold interest in a manufacturing facility in Dunkirk, New York, to ImmunityBio, Inc. (NASDAQ: IBRX), for approximately $40 million. “We are pleased with the opportunity to partner with ImmunityBio on t

Yahoo | February 15, 2022

Athenex to Present at the 11th Annual SVB Leerink Global Healthcare Conference

BUFFALO, N.Y., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Johnson Lau, CEO and Board Chairman, and Daniel Lang, President, Athenex Cell Therapy, will present at the 11 th Annual SVB Leerink Global healthcare Conference on Thursday, February 17, 2022, at 3:00 P.M. ET.

GlobeNewswire | February 9, 2022

Inside the Athenex-ImmunityBio deal — and the California company's employment plans

A relationship that began at American Pharmaceutical Partners, which had a longtime plant on Grand Island, led the immunotherapy and cell therapy company to Dunkirk.

Yahoo | January 13, 2022

Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility

BUFFALO, N.Y., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX ), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that it has entered into a definitive agreement for ImmunityBio, Inc. (NASDAQ: IBRX ) to assume its leasehold interest in a manufacturing facility in Dunkirk, New York, and certain related assets for approximately $38 million, subject to adjustment at closing. Proceeds from the sale will be used to service the Company''s debt obligations and for other general corporate purposes. The transaction is subject to customary closing conditions and is expected to close in the first quarter of 2022. Upon the closing, ImmunityBio will ...

Benzinga | January 12, 2022

SHAREHOLDER ALERT: Robbins LLP is Investigating Athenex, Inc. (ATNX) for Shareholders

SAN DIEGO, Calif. & BUFFALO, N.Y., December 29, 2021--Athenex, Inc. (ATNX) Misstated the Efficacy of its Lead Drug Candidate and the Likelihood the FDA Would Approve its New Drug Application

Yahoo | December 29, 2021

Are Options Traders Betting on a Big Move in Athenex (ATNX) Stock?

Investors need to pay close attention to Athenex (ATNX) stock based on the movements in the options market lately.

Yahoo | December 20, 2021

Athenex (ATNX) Presents At 63rd Annual Meeting of ASH - Slideshow

No summary available.

Seeking Alpha | December 14, 2021

Needham Keeps a Hold Rating on Athenex (ATNX)

Needham analyst Gil Blum maintained a Hold rating on Athenex (ATNX – Research Report) today. The company's shares closed last Monday at $1.51. According to TipRanks.com, Blum has 0 stars on 0-5 stars ranking scale with an average return of -28.1% and a 7.0% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Crispr Therapeutics AG, and Rocket Pharmaceuticals. Currently, the analyst consensus on Athenex is a Moderate Buy with an average price target of $3.50. See the top stocks recommended by analysts >> The company has a one-year high of $15.00 and a one-year low of $1.52.

Howard Kim on TipRanks | December 13, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6019 seconds.